Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model
Expert Review of Pharmacoeconomics and Outcomes Research, ISSN: 1473-7167, Vol: 8, Issue: 5, Page: 491-500
2008
- 26Citations
- 40Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations26
- Citation Indexes24
- 24
- CrossRef19
- Policy Citations2
- Policy Citation2
- Captures40
- Readers40
- 40
Article Description
To assess the epidemiological and economic impact of alternative quadrivalent human papillomavirus (HPV) vaccine strategies in Norway, we adapted a previously published dynamic transmission model. Vaccination of girls and women aged 12-24 years reduced the incidence of HPV 6/11/16/ 18-related genital warts, cervical intraepithelial neoplasia and cervical cancer by 94, 92 and 92% by year 100, respectively. The cost-effectiveness ratio for this strategy when compared with vaccinating girls before the age of 12 years only was 63,294 Norwegian kroner (€8272) per QALY gained. Based on this model and assumptions, implementation of a quadrivalent HPV vaccine national program in Norway could reduce the incidence of cervical cancer, cervical intraepithelial neoplasia and genital warts at a cost-effectiveness ratio within the range accepted as cost effective. © 2008 Expert Reviews Ltd.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know